Cellectar Biosciences, Inc. (CLRB) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $2.35, CLRB has negative trailing earnings (P/E not meaningful) and an ROE of -165.71%. Market capitalisation stands at $19M.
Balance sheet quality for CLRB: current ratio of 3.0, net cash position of $12.8M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $2.35 |
| Market Cap | $19M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.98 |
| EV / EBITDA | 0.59 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -165.71% |
| Return on Invested Capital | -74.93% |
| Return on Assets | -60.93% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Debt / Equity | 0.05 |
| Current Ratio | 6.66 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -28.56 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| CLRB | Cellectar Biosciences, Inc. | $19M | 0.98 | -165.7% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price Performance
| 1 month | -9.27% |
| 3 months | -15.77% |
| Year-to-date | -20.34% |
| 1 year | -53.56% |
| 3 years | -96.31% |
52-Week Range
| 52-week High | $6.52 |
| 52-week Low | $2.20 |
| Avg Volume (90d) | 116K |
Related companies: AEON · BOLT · CING · EVGN · IMNN · LYRA · MBIO
Explore sector: Healthcare · Biotechnology
More sections of CLRB: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks